EDVA Endovia Health Sciences, Inc.
Financings ·
An addendum with C/M Capital Master Fund lifts the facility's maximum commitment from $35 million to $135 million. The filing does not say how much stock has been sold under it.
C/M Capital Master Fund, LP is the investor. The $510,000 note converts at the lower of $1.75 and $0.01 above the closing price, and the company had $242,702 in cash and cash equivalents at June 30, 2026.
The exchange suspended trading in the company's $184.00 warrants because of their low trading price. The common stock is not affected.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $73,066 | $801,273 |
| Net income (loss) | -$25.2 million | -$23.8 million |
| Cash from operations | -$4.8 million | -$7.3 million |
| Cash and equivalents | $281,435 | $13,789 |
Our latest story on this, dated Jul 29, 2025: "Splash Beverage Group (now Endovia Health Sciences) faces NYSE American warrant delisting". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 18, 2026: "Endovia closes $510,000 secured convertible note from C/M Capital". The story links the filing or release it is based on. Read the story.
Endovia Health Sciences, Inc. trades under the ticker EDVA on AMEX.
Endovia Health Sciences, Inc. is listed on AMEX.
The SEC Central Index Key (CIK) for Endovia Health Sciences, Inc. is 1553788. Its filings are on SEC EDGAR.
6,412,521 shares as of 2026-08-19, per the cover page of its 10-Q filed 2026-08-19.
Our directory records Endovia Health Sciences, Inc. under United States.
Our directory classifies Endovia Health Sciences, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Endovia Health Sciences, Inc. is US84862C4015.
aibio.space lists Endovia Health Sciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
$73,066 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Endovia Health Sciences, Inc. reported a net loss of $25.2 million for the fiscal year ended Dec 31, 2025, and used $4.8 million of cash in operations, per its annual report to the SEC.
$242,702 in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Endovia Health Sciences, dated Oct 27, 2026: "Endovia Health Sciences raises equity line ceiling to $135 million". An addendum with C/M Capital Master Fund lifts the facility's maximum commitment from $35 million to $135 million. The filing does not say how much stock has been sold under it. Source.
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,1.02,3.01,3.02,5.03,7.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,3.02,5.03,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Filed to remove its shares from exchange listing. SEC Form 25-NSE. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.02,5.03). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio